文献速递乳腺癌

高风险乳腺病变或浸润前乳腺癌诊断后用于一级和二级预防的内分泌治疗

Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-05-01

本文讨论高风险乳腺病变(HRL)和导管原位癌(DCIS)患者的内分泌预防策略。HRL患者按绝经状态可选他莫昔芬20 mg每日1次用5年、他莫昔芬5 mg每日1次用3年(近新增)、雷洛昔芬或芳香化酶抑制剂(后两者用于绝经后);DCIS患者放疗基础上加内分泌治疗获益小,主要来自对侧乳腺诊断或新发乳腺癌的减少。作者推荐共同决策并关注患者风险耐受与副作用偏好,认为低剂量他莫昔芬耐受性好且风险降低与其他方案相当。

要点

  • HRL患者内分泌治疗降低未来乳腺癌诊断风险但不改善生存,需权衡副作用与获益。
  • HRL化学预防方案因绝经状态而异:他莫昔芬20 mg每日1次用5年或5 mg每日1次用3年;绝经后可用雷洛昔芬或芳香化酶抑制剂。
  • DCIS放疗基础上加内分泌治疗获益小,主要来自对侧乳腺诊断或新发乳腺癌的减少。

核心结论

  • HRL或浸润前乳腺癌患者内分泌治疗降低未来乳腺癌诊断风险但不改善生存,须权衡副作用与获益。
  • 作者推荐共同决策并关注患者风险耐受与副作用偏好,认为低剂量他莫昔芬耐受性好、无严重不良事件风险且风险降低与其他方案相当。

研究设计与样本

  • 本文为Oncology Grand Rounds系列综述,以病例展示引出诊断与管理挑战,复习相关文献并总结作者建议的管理方法。

主要发现

  • HRL患者化学预防方案因绝经状态而异:绝经前和绝经后均可选他莫昔芬20 mg每日1次用5年,近新增他莫昔芬5 mg每日1次用3年;绝经后还可选雷洛昔芬或芳香化酶抑制剂。
  • DCIS患者放疗基础上加内分泌治疗获益小,似乎主要来自对侧乳腺诊断或新发乳腺癌的减少。
  • 低剂量他莫昔芬耐受性好、无严重不良事件风险,风险降低与其他方案相当。

关键数值与推荐

  • HRL化学预防:他莫昔芬20 mg每日1次用5年(绝经前和绝经后);他莫昔芬5 mg每日1次用3年(绝经前和绝经后,近新增);雷洛昔芬或芳香化酶抑制剂(绝经后)。
  • 作者推荐共同决策并关注患者风险耐受与副作用偏好。
  • 作者认为低剂量他莫昔芬是尤其有利的选择,耐受性好、无严重不良事件风险且风险降低与其他方案相当。

临床怎么用

  • 作者推荐对HRL患者采用共同决策,关注患者风险耐受与副作用偏好。
  • 作者认为低剂量他莫昔芬是尤其有利的选择,耐受性好、无严重不良事件风险且风险降低与其他方案相当。
  • 作者认为在二级预防背景下,降低化学预防副作用谱的策略如低剂量他莫昔芬可能尤其有吸引力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Patients with high-risk breast lesions (HRLs) or preinvasive breast cancers face an elevated risk of future breast cancer diagnoses. Endocrine therapy in this setting reduces the risk of a future diagnosis but does not confer improved survival, thus the side effects of primary/secondary prevention must be considered relative to the benefits. Here, we discuss the available chemoprevention regimens for patients with HRLs and considerations for selecting a regimen, as well as the decision making surrounding use of adjuvant endocrine therapy for patients with ductal carcinoma in situ (DCIS). For patients with HRLs, available chemoprevention regimens differ by menopausal status, including tamoxifen 20 mg once daily for 5 years and more recently tamoxifen 5 mg once daily for 3 years in both premenopausal and postmenopausal women as well as raloxifene or aromatase inhibitors for postmenopausal women. We recommend a shared decision-making approach with attention to patient preferences related to risk tolerance and side-effect profiles. Low-dose tamoxifen appears to be a particularly favorable choice that is well tolerated, without risk of serious adverse events and offers comparable risk reduction to other regimens. For DCIS, the benefit of endocrine therapy in addition to radiation is small, and appears to be driven mainly by a reduction in contralateral breast diagnoses or new breast cancers. A strategy that reduces the side-effect profile of chemoprevention such as low-dose tamoxifen may be especially appealing in the setting of secondary prevention.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Laws A, Punglia RS. Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer. J Clin Oncol. 2023. PMID: 37126767. doi:10.1200/JCO.23.00455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。